INTS – intensity therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cance
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cance
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement [Yahoo! Finance]
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Intensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS
Form SCHEDULE 13G INTENSITY THERAPEUTICS, Filed by: SAPIENT CAPITAL LLC
Form 424B3 INTENSITY THERAPEUTICS,
Form EFFECT INTENSITY THERAPEUTICS,
Form S-1 INTENSITY THERAPEUTICS,
Form D INTENSITY THERAPEUTICS,
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.